Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services symbols : Alzn save search
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients
Published: 2023-12-11 (Crawled : 15:30) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -1.87%
H: 0.0%
C: -4.76%
al001 fda drug lithium trial
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
Published: 2023-11-16 (Crawled : 14:30) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 1.33%
H: 0.0%
C: -2.63%
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -6.85%
al001 drug candidate lithium application trial
Alzamend Neuro Announces Reverse Stock Split
Published: 2023-10-30 (Crawled : 15:30) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -26.31%
H: 7.96%
C: 2.29%
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001
Published: 2023-10-23 (Crawled : 13:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.55%
H: 0.79%
C: -1.14%
al001 drug candidate lithium application trial
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
Published: 2023-10-02 (Crawled : 13:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -2.87%
H: 4.26%
C: -5.78%
al001 fda drug lithium trial
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
Published: 2023-09-22 (Crawled : 13:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -1.7%
H: 4.4%
C: -2.27%
nasdaq granted extension
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
Published: 2023-08-30 (Crawled : 15:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.07%
H: 3.21%
C: 0.0%
al001 drug lithium application trial
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
Published: 2023-06-22 (Crawled : 18:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -3.75%
H: 7.58%
C: 1.79%
al001 positive trial results
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2023-04-04 (Crawled : 18:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 2.04%
H: 1.0%
C: -0.5%
alzn002 vaccine alzheimer’s dementia immunotherapy trial initiated
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2023-04-03 (Crawled : 14:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 3.53%
H: 24.55%
C: 11.36%
alzn002 vaccine alzheimer’s dementia immunotherapy trial
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 8.93%
H: 0.85%
C: -4.48%
al001 alzheimer’s treatment dementia trial
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
Published: 2023-03-16 (Crawled : 13:20) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 4.3%
H: 0.0%
C: -8.72%
business update financial results
Alzamend Neuro to Present at Sequire Biotechnology Conference
Published: 2023-01-26 (Crawled : 15:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -0.02%
H: 9.68%
C: 9.5%
conference
Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial
Published: 2023-01-04 (Crawled : 14:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 3.45%
H: 0.0%
C: -3.35%
trial group
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
Published: 2022-11-15 (Crawled : 13:20) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 1.87%
H: 3.67%
C: 2.75%
ceo
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2022-10-31 (Crawled : 15:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 1.77%
H: 6.09%
C: 1.74%
alzn002 fda dementia drug immunotherapy vaccine application trial alzheimer’s
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
Published: 2022-10-05 (Crawled : 16:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -1.45%
H: 8.82%
C: 8.82%
al001 ongoing trial alzheimer’s
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2022-09-29 (Crawled : 13:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -3.39%
H: 7.02%
C: 4.39%
alzn002 dementia immunotherapy application trial alzheimer’s
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
Published: 2022-09-22 (Crawled : 13:20) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -3.05%
H: 0.79%
C: -4.72%
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.